Farzana Perwad

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 4

Top Topics

Neuropathic Pain

Monoclonal Antibody

Placebo Controlled

Top Venues

medRxiv : the preprint server for health sciences

Calcified tissue international

This page only lists publications with an associated author ORCID identifier.

Publications

Farzana Perwad, Elvis A Akwo, Nicholas Vartanian, Larrry J Suva, Peter A Friedman, Cassianne Robinson-Cohen
Multi-trait Analysis of GWAS for circulating FGF23 Identifies Novel Network Interactions Between HRG-HMGB1 and Cardiac Disease in CKD. medRxiv : the preprint server for health sciences (2024)
Farzana Perwad, Elvis A Akwo, Nicholas Vartanian, Larrry J Suva, Peter A Friedman, Cassianne Robinson-Cohen
Multi-trait Analysis of GWAS for circulating FGF23 Identifies Novel Network Interactions Between HRG-HMGB1 and Cardiac Disease in CKD. medRxiv : the preprint server for health sciences (2024)
Maria Luisa Brandi, Suzanne M Jan de Beur, Karine Briot, Thomas O Carpenter, Hae Il Cheong, Martine Cohen Solal, Rachel Katherine Crowley, Richard Eastell, Yasuo Imanishi, Erik Allen Imel, Steven W Ing, Karl L Insogna, Nobuaki Ito, Muhammad Kassim Javaid, Peter Kamenickỷ, Richard Keen, Takuo Kubota, Robin H Lachmann, Farzana Perwad, Pisit Pitukcheewanont, Anthony A Portale, Stuart H Ralston, Hiroyuki Tanaka, Thomas J Weber, Han Wook Yoo, Wei Sun, Angela Williams, Annabel Nixon, Yasuhiro Takeuchi
Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study. Calcified tissue international 111 (4) (2022)
Raja Padidela, Michael P Whyte, Francis H Glorieux, Craig Frank Munns, Leanne M Ward, Ola Nilsson, Anthony A Portale, Jill H Simmons, Noriyuki Namba, Hae Il Cheong, Pisit Pitukcheewanont, Etienne Sochett, Wolfgang Högler, Koji Muroya, Hiroyuki Tanaka, Gary S Gottesman, Andrew Biggin, Farzana Perwad, Angela Williams, Annabel Nixon, Wei Sun, Angel Chen, Alison Skrinar, Erik Allen Imel
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. Calcified tissue international 108 (5) (2021)